Supplementary Table 3 from Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT–Identified Oligometastatic Castration-Resistant Prostate Cancer

Autor: Sean S. Park, Haidong Dong, Eugene D. Kwon, Thomas M. Pisansky, Kenneth R. Olivier, Mark A. Nathan, Geoffrey B. Johnson, Brian A. Costello, William S. Harmsen, J. Fernando Quevedo, Brian J. Davis, Matthew J. Iott, Debra H. Brinkmann, C. Richard Choo, Lance C. Pagliaro, Michael S. Bold, Erik J. Tryggestad, Fabrice Lucien, Val J. Lowe, B.J. Stish, Feven Abraha, Jacob J. Orme, Henan Zhang
Rok vydání: 2023
DOI: 10.1158/1078-0432.22484210.v1
Popis: Supplementary Table 3. Baseline TTR and changes after SBRT predict outcomes in oligometastatic CRPC. Median event-free survival survival (in months) and hazard ratio for each outcome and group is given, stratified by baseline TTR levels (left) or change in TTR levels from baseline to day 14 post-SBRT. ns not significant; N/A not applicable
Databáze: OpenAIRE